Remifentanil (DrugBank: Remifentanil)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 2 |
70 | Spinal stenosis | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1900021760 | 2019-03-09 | 2019-03-08 | Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol | Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol | Parkinson’s disease | Parkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil; | The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China | NULL | Recruiting | 40 | 64 | Male | Parkinson’s disease:25;Non-Parkinson’s disease:25; | N/A | China |
2 | NCT00615472 (ClinicalTrials.gov) | October 2003 | 9/1/2008 | Intravenous Versus Inhalational Anesthesia in Parkinson's Disease | Intravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's Disease | Parkinson's Disease | Drug: Isoflurane;Drug: Remifentanil;Drug: Propofol | Columbia University | NULL | Terminated | 18 Years | N/A | All | 58 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-TRC-13003639 | 2012-09-13 | 2013-09-07 | The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery | The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery | Lumbar spinal stenosis and/or lumbar intervertebral disc herniation | ANI group:ANI guide the administration of remifentanil;control group:remifentanil was adapted by Anaesthesiologist corresponding to clinical experiences ; | Peking University Third Hospital | NULL | Completed | 18 | 70 | Both | ANI group:30;control group:30; | China | |
2 | NCT01052324 (ClinicalTrials.gov) | March 2010 | 11/1/2010 | The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation | The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation | Cervical Disc Herniation;Cervical Spinal Stenosis;Cervical Spine Damage | Drug: Remifentanil | Yonsei University | NULL | Completed | 20 Years | 65 Years | Both | 19 | Phase 4 | Korea, Republic of |